Delivery Order SPE2DB20D3103-SPE2DB25FQ1Z3
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,757.28 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. The contract, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,715.91 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a non-set-aside competitive award. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $21,626.20 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $38,677.92 to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive award under the company's existing indefinite delivery contract with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $18,202.15 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed price delivery order, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.76 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, issued on August 29, 2025, is set to be completed by September 2, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside restrictions, reflecting the contractor's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $32,838.00 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. The contract, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ1Z3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,143.94 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal healthcare procurement needs. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems and other federal agencies including the Defense Health Agency and U.S. Coast Guard. Actemra, a biologic treatment for rheumatoid arthritis and other inflammatory conditions, represents the type of specialized pharmaceutical commodity that supports the military medical supply chain through this flexible contract framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/8/25 |